Megakaryocytic emperipolesis and platelet function abnormalities in five patients with gray platelet syndrome

Platelets

Volumn 26, Issue 8, 2015, Pages 751-757

  Larocca, Luigi M ^a   Heller, Paula G ^b   Podda, Gianmarco ^c   Pujol Moix, Nuria ^d   Glembotsky, Ana C ^b   Pecci, Alessandro ^e   Alberelli, Maria Adele ^a   Balduini, Carlo L ^e   Landolfi, Raffaele ^a   Cattaneo, Marco ^c   De Candia, Erica ^a  

^a FONDAZIONE POLICLINICO UNIVERSITARIO A GEMELLI IRCCS   (Italy)

^b INSTITUTO DE INVESTIGACIONES MÉDICAS ALFREDO LANARI   (Argentina)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e UNIVERSITY OF PAVIA   (Italy)

Author keywords

Emperipolesis; gray platelet syndrome; megakaryocytes; PAR1 receptor; platelet disorder

Indexed keywords

FIBRINOGEN; PADGEM PROTEIN; PROTEINASE ACTIVATED RECEPTOR 1; THROMBIN; THROMBOCYTE FACTOR 4; ADENOSINE TRIPHOSPHATE; NBEAL2 PROTEIN, HUMAN; PLASMA PROTEIN;

AGED; ANTIBODY LABELING; ARTICLE; BONE MARROW BIOPSY; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; EMPERIPOLESIS; FIBROSIS; GRAY PLATELET SYNDROME; HUMAN; HUMAN TISSUE; MEGAKARYOCYTE; MEGAKARYOCYTIC EMPERIPOLESIS; MOLECULAR GENETICS; PRIORITY JOURNAL; THROMBOCYTE FUNCTION; THROMBOCYTE MEMBRANE; BLOOD CLOTTING PARAMETERS; BONE MARROW; CASE CONTROL STUDY; CELL GRANULE; GENE EXPRESSION; GENETICS; METABOLISM; MUTATION; PATHOLOGY; SECRETION (PROCESS); THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION;

ADENOSINE TRIPHOSPHATE; AGED; BLOOD PLATELETS; BLOOD PROTEINS; BONE MARROW; CASE-CONTROL STUDIES; CYTOPLASMIC GRANULES; EMPERIPOLESIS; FIBROSIS; GENE EXPRESSION; GRAY PLATELET SYNDROME; HUMANS; MEGAKARYOCYTES; MUTATION; PLATELET ACTIVATION; PLATELET AGGREGATION; PLATELET FUNCTION TESTS; RECEPTOR, PAR-1;

EID: 84942988525     PISSN: 09537104     EISSN: 13691635     Source Type: Journal    
DOI: 10.3109/09537104.2014.994093     Document Type: Article

References (37)

1. Raccuglia G. Gray platelet syndrome. A variety of qualitative platelet disorder. Am J Med 1971;51:818-828.
2. Kahr WH, Hinckley J, Li L, Schwertz H, Christensen H, Rowley JW, Pluthero FG, Urban D, Fabbro S, Nixon B, et al. Mutations in NBEAL2, encoding a BEACH protein, cause gray platelet syndrome. Nat Genet 2011;43:738-740.
3. Gunay-Aygun M, Falik-Zaccai TC, Vilboux T, Zivony-Elboum Y, Gumruk F, Cetin M, Khayat M, Boerkoel CF, Kfir N, Huang Y, et al. NBEAL2 is mutated in gray platelet syndrome and is required for biogenesis of platelet alpha-granules. Nat Genet 2011;43:732-734.
4. Albers CA, Cvejic A, Favier R, Bouwmans EE, Alessi MC, Bertone P, Jordan G, Kettleborough RN, Kiddle G, Kostadima M, et al. Exome sequencing identifies NBEAL2 as the causative gene for gray platelet syndrome. Nat Genet 2011;43:735-737.
5. Bottega R, Pecci A, De Candia E, Pujol-Moix N, Heller PG, Noris P, De Rocco D, Podda GM, Glembotsky AC, Cattaneo M, et al. Correlation between platelet phenotype and NBEAL2 genotype in patients with congenital thrombocytopenia and alpha-granule deficiency. Haematologica 2013;98:868-874.
6. Kahr WH, Lo RW, Li L, Pluthero FG, Christensen H, Ni R, Vaezzadeh N, Hawkins CE, Weyrich AS, Di Paola J, et al. Abnormal megakaryocyte development and platelet function in Nbeal2(-/-) mice. Blood 2013;122:3349-3358.
7. Deppermann C, Cherpokova D, Nurden P, Schulz JN, Thielmann I, Kraft P, Vögtle T, Kleinschnitz C, Dütting S, Krohne G, et al. Gray platelet syndrome and defective thrombo-inflammation in Nbeal2-deficient mice. J Clin Invest 2013;123:3331-3342.
8. Guerrero JA, Bennett C, van der Weyden L, McKinney H, Chin M, Nurden P, McIntyre Z, Cambridge EL, Estabel J, Wardle-Jones H, et al. Gray platelet syndrome: Pro-inflammatory megakaryocytes and alpha-granule loss cause myelofibrosis and confer resistance to cancer metastasis in mice. Blood 2014;124:3624-3635. [Epub ahead of print].
9. Monteferrario D, Bolar NA, Marneth AE, Hebeda KM, Bergevoet SM, Veenstra H, Laros-van Gorkom BA, MacKenzie MA, Khandanpour C, Botezatu L, et al. A dominant-negative GFI1B mutation in the gray platelet syndrome. N Engl J Med 2014;370: 245-253.
10. Gerrard JM, Phillips DR, Rao GH, Plow EF, Walz DA, Ross R, Harker LA, White JG. Biochemical studies of two patients with the gray platelet syndrome. Selective deficiency of platelet alpha granules. J Clin Invest 1980;66:102-109.
11. Levy-Toledano S, Caen JP, Breton-Gorius J, Rendu F, Cywiner-Golenzer C, Dupuy E, Legrand Y, Maclouf J. Gray platelet syndrome: Alpha-granule deficiency. Its influence on platelet function. J Lab Clin Med 1981;98:831-848.
12. Mori K, Suzuki S, Sugai K. Electron microscopic and functional studies on platelets in gray platelet syndrome. Tohoku J Exp Med 1984;143:261-287.
13. Srivastava PC, Powling MJ, Nokes TJ, Patrick AD, Dawes J, Hardisty RM. Grey platelet syndrome: Studies on platelet alphagranules, lysosomes and defective response to thrombin. Br J Haematol 1987;65:441-446.
14. Facon T, Goudemand J, Caron C, Zandecki M, Estienne MH, Fenaux P, Cosson A. Simultaneous occurrence of grey platelet syndrome and idiopathic pulmonary fibrosis: A role for abnormal megakaryocytes in the pathogenesis of pulmonary fibrosis? Br J Haematol 1990;74:542-543.
15. Pfueller SL, Howard MA, White JG, Menon C, Berry EW. Shortening of bleeding time by 1-deamino-8-arginine vasopressin (DDAVP) in the absence of platelet von Willebrand factor in Gray platelet syndrome. Thromb Haemost 1987;58:1060-1063.
16. Kohler M, Hellstern P, Morgenstern E, Mueller-Eckhardt C, Berberich R, Meiser RJ, Scheffler P, Wenzel E. Gray platelet syndrome: Selective alpha-granule deficiency and thrombocytopenia due to increased platelet turnover. Blut 1985;50:331-340.
17. Nurden P, Jandrot-Perrus M, Combrie R, Winckler J, Arocas V, Lecut C, Pasquet JM, Kunicki TJ, Nurden AT. Severe deficiency of glycoprotein VI in a patient with gray platelet syndrome. Blood 2004;104:107-114.
18. Jantunen E, Hanninen A, Naukkarinen A, Vornanen M, Lahtinen R. Gray platelet syndrome with splenomegaly and signs of extramedullary hematopoiesis: A case report with review of the literature. Am J Hematol 1994;46:218-224.
19. De Candia E, Pecci A, Ciabattoni G, De Cristofaro R, Rutella S, Yao-Wu Z, Lazzareschi I, Landolfi R, Coughlin S, Balduini CL. Defective platelet responsiveness to thrombin and protease-activated receptors agonists in a novel case of gray platelet syndrome: Correlation between the platelet defect and the alpha-granule content in the patient and four relatives. J Thromb Haemost 2007; 5:551-559.
20. Gunay-Aygun M, Zivony-Elboum Y, Gumruk F, Geiger D, Cetin M, Khayat M, Kleta R, Kfir N, Anikster Y, Chezar J, et al. Gray platelet syndrome: Natural history of a large patient cohort and locus assignment to chromosome 3p. Blood 2010;116:4990-5001.
21. Falik-Zaccai TC, Anikster Y, Rivera CE, Horne 3rd MK, Schliamser L, Phornphutkul C, Attias D, Hyman T, White JG, Gahl WA. A new genetic isolate of gray platelet syndrome (GPS): Clinical, cellular, and hematologic characteristics. Mol Genet Metab 2001;74:303-313.
22. Cattaneo M. Light transmission aggregometry and ATP release for the diagnostic assessment of platelet function. Semin Thromb Hemost 2009;35:158-167.
23. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005;90:1128-1132.
24. Molino M, Bainton DF, Hoxie JA, Coughlin SR, Brass LF. Thrombin receptors on human platelets. Initial localization and subsequent redistribution during platelet activation. J Biol Chem 1997;272:6011-6017.
25. Mihara K, Ramachandran R, Renaux B, Saifeddine M, Hollenberg MD. Neutrophil elastase and proteinase-3 trigger G protein-biased signaling through proteinase-activated receptor-1 (PAR1). J Biol Chem 2013;288:32979-32990.
26. Sambrano GR, Huang W, Faruqi T, Mahrus S, Craik C, Coughlin SR. Cathepsin G activates protease-activated receptor-4 in human platelets. J Biol Chem 2000;275:6819-6823.
27. Trivedi V, Boire A, Tchernychev B, Kaneider NC, Leger AJ, O'Callaghan K, Covic L, Kuliopulos A. Platelet matrix metalloprotease-1 mediates thrombogenesis by activating PAR1 at a cryptic ligand site. Cell 2009;137:332-343.
28. Ludeman MJ, Zheng YW, Ishii K, Coughlin SR. Regulated shedding of PAR1 N-terminal exodomain from endothelial cells. J Biol Chem 2004;279:18592-18599.
29. Lages B, Sussman, II, Levine SP, Coletti D, Weiss HJ. Platelet alpha granule deficiency associated with decreased P-selectin and selective impairment of thrombin-induced activation in a new patient with gray platelet syndrome (alpha-storage pool deficiency). J Lab Clin Med 1997;129:364-375.
30. Nurden AT, Nurden P. The gray platelet syndrome: Clinical spectrum of the disease. Blood Rev 2007;21:21-36.
31. Schmitt A, Jouault H, Guichard J, Wendling F, Drouin A, Cramer EM. Pathologic interaction between megakaryocytes and polymorphonuclear leukocytes in myelofibrosis. Blood 2000;96: 1342-1347.
32. Centurione L, Di Baldassarre A, Zingariello M, Bosco D, Gatta V, Rana RA, Langella V, Di Virgilio A, Vannucchi AM, Migliaccio AR. Increased and pathologic emperipolesis of neutrophils within megakaryocytes associated with marrow fibrosis in GATA-1(low) mice. Blood 2004;104:3573-3580.
33. Yan XQ, Lacey D, Hill D, Chen Y, Fletcher F, Hawley RG, McNiece IK. A model of myelofibrosis and osteosclerosis in mice induced by overexpressing thrombopoietin (mpl ligand): Reversal of disease by bone marrow transplantation. Blood 1996;88:402-409.
34. White JG. Ultrastructural studies of the gray platelet syndrome. Am J Pathol 1979;95:445-462.
35. Breton-Gorius J, Vainchenker W, Nurden A, Levy-Toledano S, Caen J. Defective alpha-granule production in megakaryocytes from gray platelet syndrome: Ultrastructural studies of bone marrow cells and megakaryocytes growing in culture from blood precursors. Am J Pathol 1981;102:10-19.
36. Tefferi A. Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol 2005;23:8520-8530.
37. Heller PG, Glembotsky AC, Goette NP, Marta RF, Lev PR, Molinas FC. Diverse Mpl expression pattern among pedigrees with inherited thrombocytopenia: Potential diagnostic and therapeutic implications. J Thromb Haemost 2008;6:2215-2217.